Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Crenigacestat (Primary) ; Gemcitabine (Primary) ; Samotolisib (Primary) ; Taladegib (Primary)
  • Indications Advanced breast cancer; Cholangiocarcinoma; Colon cancer; Lymphoma; Male breast cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 21 Aug 2025 Number of arms changed to 12. Experimental arms: Part C:25 mg LY3039478+100 mg Abemaciclib Cohort 1, Part C:50 mg LY3039478+100 mg Abemaciclib Cohort 2, Part C:25 mg LY3039478+150 mg Abemaciclib Cohort 3, Part D:25 mg LY3039478+25 mg/m2 Cisplatin+1000 mg/m2 Gemcitabine Cohort 1, Part D:50 mg LY3039478+25 mg/m2 Cisplatin+1000 mg/m2 Gemcitabine Cohort 2, added to study protocol.
  • 21 Aug 2025 Status changed from completed to discontinued due to business considerations.
  • 16 Sep 2022 Results reporting on group 2 of 5, published in the Cancer Chemotherapy and Pharmacology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top